# US 2025/0129012 A1 · Anti-inflammatory and analgesic compounds and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0129012 A1
- Document ID: US20250129012A1
- Status: Published application
- Kind: A1
- Application number: 18/711,128
- Filed: 2022-05-05
- Published: 2025-04-24
- Earliest claimed: 2021-11-18
- Assignees: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
- Inventors: Dongfang SHI; Changjin FU; Yan YANG; Haiming LI
- Web page: https://patentgrep.com/patent/US20250129012A1

## CPC

- C07C 235/36: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07F 5/025: {Boronic and borinic acid compounds}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/402: 1-aryl substituted, e.g. piretanide
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/415: 1,2-Diazoles
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07C 233/32: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C07C 233/50: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C 233/58: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 235/30: the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
- C07C 235/84: with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 255/60: at least one of the singly-bound nitrogen atoms being acylated
- C07C 271/30: to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
- C07C 275/26: having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 311/46: Y being a hydrogen or a carbon atom
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 207/263: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D 211/40: Oxygen atoms
- C07D 211/76: attached in position 2 or 6
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/61: with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 249/06: with aryl radicals directly attached to ring atoms
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 257/04: Five-membered rings
- C07D 263/22: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
- C07D 263/24: with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- C07D 265/32: with oxygen atoms directly attached to ring carbon atoms
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/192: from aromatic carboxylic acids
- C07D 307/20: Oxygen atoms
- C07D 317/70: condensed with ring systems containing two or more relevant rings
- C07C 2603/32: Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

It belongs to the field of medicinal chemistry, in particular discloses anti-inflammatory and analgesic compounds and use thereof, the compounds of the present invention are compounds, isomers or pharmaceutically acceptable salts as shown in formula (I) or formula (II); the compounds have significant curative effect on gouty arthritis in rats, and have excellent anti-inflammatory factor effect; therefore, the compounds have potential application prospects in anti-inflammatory and analgesic drugs, especially in anti-acute gouty arthritis drugs, anti-rheumatoid arthritis drugs, drugs to reduce inflammatory factors, drugs to treat inflammatory storm or coronavirus pneumonia.

## Claims

### Claim 1

A compound has the structure shown in formula (I) or formula (II), or isomer and pharmaceutically acceptable salt thereof,
wherein,
R1, R2, R3, or R4 are independently hydrogen, deuterium, halogen, cyano, C1-3 alkoxy, hydroxyl, aldehyde group, carboxyl, C2-6 ester, amide, substituted amide, C1-3 alkyl, substituted C1-3 alkoxy, or substituted C1-3 alkyl, respectively, the said substituent is one or more selected from the group consisting of deuterium, halogen, hydroxyl, carboxyl, C1-3 alkyl or cyano;
alternatively, two adjacent groups in R1, R2, R3 and R4 are joined together to form —O—R17—O— group, wherein R17 is C1-6 alkyl;
R5, R6, R7 or R8 are independently hydrogen, deuterium, halogen, hydroxyl, cyano, carboxyl, C2-6 ester group or substituted or non-substituted groups of amino, amide, C1-3 alkoxy or C1-3 alkyl, the said substituent is one or more selected from the group consisting of deuterium, halogen, cyano, C1-3 alkyl or C1-3 haloalkyl;
R9 is hydrogen, C1-4 alkyl, or C1-4 substituted alkyl, the said substituent is one or more selected from the group consisting of deuterium, hydroxyl, C1-2 alkoxy, or cyano;
X is —C(═O)—, —S(═O)2—, —S(═O)—, —C(═NH)— or substituted —C(═NH)—, the substituent is selected from CN and SO2NH2;
R10 is C1-4 alkyl, substituted C1-4 alkyl, C3-6 cycloalkyl, substituted C3-6 cycloalkyl, amino, C1-4 alkylamino, substituted C1-4 alkylamino, C3-6 cycloalkylamino, C1-4 alkoxy, substituted C1-4 alkoxy, or vinyl; or R9 is attached to R10 so that R9—N—X—R10 forms a ring group together; the said substituent is selected from one or more of deuterium, halogen and cyano;
R11 is hydrogen, deuterium, halogen, cyano, C1-2 alkyl, C1-2 alkoxy, carboxyl, or C1-3 alkyl substituted amide;
R12 is a hydrogen, deuterium, halogen, hydroxyl, cyano, carboxyl, or substituted or non-substituted group of the following: C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, morpholinyl, aminocarbonyl, C1-4 alkylamino carbonyl, or C1-4 alkoxy carbonyl; the substituent is selected from one or more of deuterium, halogen or cyano; and
(a) when R12 is hydrogen, R13 is cyano, aldehyde group, carboxyl, borono, substituted C1-4 alkoxy, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, phenyl amino carbonyl, pyridinyl amino carbonyl, C1-4 alkylamino carbonyl, C1-4 alkoxy carbonyl, C1-4 alkylamino carbonyl amino, C2-6 heterocycloalkyl carbonyl, C3-6 heterocycloalkyl ketone group, C1-2 alkyl carbonyl, sulfonamido, sulfonyloxy, amino sulfonyl, amino sulfonyloxy, C1-4 alkyl sulfonamido, C1-4 alkyl amino sulfonyl, C1-4 alkyl amino sulfonamido, C1-4 alkyl sulfonyloxy, C1-4 alkyl amino sulfonyloxy, C1-4 alkyl amino carbonyloxy, tetrazolyl, triazolyl, imidazolyl, morpholinyl, C1-4 alkyl thio, C3-6 cycloalkoxy or C3-6 heterocycloalkyloxy, the substituent is selected from one or more of deuterium, halogen, cyano, hydroxyl, phenyl, pyridyl, C1-3 alkyl, C1-3 deuteroalkyl or C1-3 haloalkyl;
(b) when R12 is not hydrogen, R13 is cyano, aldehyde group, carboxyl, borono, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, phenyl amino carbonyl, pyridinyl amino carbonyl, C1-4 alkylamino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkylamino carbonyl amino, C2-6 heterocycloalkyl carbonyl, C3-6 heterocycloalkyl ketone group, C1-4 alkyl carbonyl, sulfonamido, sulfonyloxy, sulfamoyl, sulfamoyloxy, C1-4 alkyl sulfonamido, C1-4 alkyl amino sulfonyl, C1-4 alkyl amino sulfonamido, C1-4 alkyl sulfonyloxy, C1-4 alkyl amino sulfonyloxy, C1-4 alkyl amino carbonyloxy, heterocyclic group, C1-4 alkyl amino, C3-6 cycloalkyl amino, C3-6 heterocycloalkyloxy, C3-6 heterocycloalkyl amino, C1-4 alkyl carbonyl amino, C1-4 alkoxy, C1-4 alkylthio, C3-6 cycloalkoxy, C3-6 heterocyclo alkyl or C1-4 alkyl, the substituent is selected from one or more of deuterium, halogen, cyano, hydroxyl, phenyl, pyridyl, C1-3 alkyl, C1-3 deuteroalkyl and C1-3 haloalkyl;
R14 is a cyano, carboxyl, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, C2-6 heterocycloalkyl carbonyl, sulfamoyl, C1-4 alkylaminosulfonyl, heterocyclic, C3-6 heterocycloalkyl, C3-6 heterocycloalkyloxy, C1-4 alkoxy, C3-6 cycloalkoxy, C3-6 heterocycloalkoxy or C1-4 alkyl, the substituent is selected from one or more of deuterium, halogen, cyano, hydroxyl, C1-3 alkyl and C1-3 haloalkyl;
R15 is hydrogen, deuterium, halogen, cyano, C1-2 alkyl, C1-2 alkoxy, carboxyl, or C1-3 alkyl substituted amide;
provided that the following conditions are excluded:
(i) In formula (I), when R1-R3 is methoxy, R4-R9 is hydrogen, R10 is methyl, R11-R12 is hydrogen, and R15 is hydrogen, R13 is selected from the following groups: C1-4 alkoxy, C1-4 alkylthio, deutero C1-4 alkylthio, C1-4-alkoxy carbonyl amino, butyl carbonyl, or morpholinyl;
(ii) In formula (I), R1-R3 is methoxy, R4-R9 is hydrogen, R10 is deuteromethyl, R11 is hydrogen, R12 is deuterium, R13 is methoxy, and R15 is deuterium;
(iii) In formula (I), R1-R3 is methoxy, R4-R9 is hydrogen, R10 is methyl, R11 is hydrogen, R12 is bromine, R13 is methoxy, and R15 is bromine.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound has the structure shown in formula (III) or formula (IV),
R1, R2, R3, or R4 are independently hydrogen, deuterium, halogen, cyano, C1-3 alkoxy, aldehyde group, C1-3 alkyl, substituted C1-3 alkoxy, or substituted C1-3 alkyl, respectively, wherein the substituent is one or more selected from the group consisting of deuterium, halogen, C1-3 alkyl, and cyano;
alternatively, R1 and R2, R2 and R3, or R3 and R4 are joined together to form the —O—R17—O— group, wherein R17 is C1-3 alkyl;
R5, R6, R7, or R8 is independently hydrogen, deuterium, halogen, cyano, carboxyl, hydroxyl, or amino, respectively;
R9 is hydrogen, C1-4 alkyl, or C1-4 substituted alkyl, wherein the substituent is one or more selected from the group consisting of deuterium, hydroxyl, C1-2 alkoxy, and cyano;
X is —C(═O)— or —S(═O)2— group;
R10 is a C1-4 alkyl, substituted C1-4 alkyl, C3-6 cycloalkyl, substituted C3-6 cycloalkyl, amino, C1-4-alkyl amino, substituted C1-4-alkyl amino, C3-6 cycloalkyl amino, C1-4 alkoxy, substituted C1-4 alkoxy, or vinyl, or R9—N—X—R10 forms
the substituent is selected from one or more of deuterium and cyano;
R11 is hydrogen, deuterium, halogen, cyano, C1-2 alkyl, C1-2 alkoxy, carboxyl, or C1-3 alkyl substituted amide;
R12 is hydrogen, deuterium, halogen, hydroxyl, cyano, or substituted or non-substituted group of the following: C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, morpholinyl, C1-4 alkylamino carbonyl or C1-4-alkoxy carbonyl; the substituent is selected from one or more of deuterium, halogen and cyano; and
(a) when R12 is hydrogen, R13 is a cyano, aldehyde group, carboxyl, borono, substituted C1-4 alkoxy, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, phenyl amino carbonyl, pyridinyl amino carbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, pyrrolidyl carbonyl, piperazinyl carbonyl, morpholinyl carbonyl, pyrrolidonyl, oxazolidinonyl, morpholinonyl, C1-2 alkyl carbonyl, sulfonamido, sulfonyloxy, amino sulfonyl, amino sulfonyloxy, C1-4 alkyl sulfonamido, C1-4 alkyl amino sulfonyl, C1-4 alkyl amino sulfonamido, C1-4 alkyl amino sulfonyloxy, C1-4 alkyl amino carbonyloxy, tetrazolyl, triazolyl, imidazolyl, morpholinyl, C1-4 alkyl thio, C3-6 cycloalkyloxy or tetrahydrofuranyloxy, the substituent is one or more selected from the group consisting of deuterium, halogen, cyano, hydroxyl, phenyl, C1-3 alkyl, C1-3 deuteroalkyl or C1-3 haloalkyl;
(b) when R12 is not hydrogen, R13 is cyano, aldehyde group, carboxyl, borono, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, phenyl amino carbonyl, pyridinyl amino carbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, C2-6 heterocycloalkyl carbonyl, C3-6 heterocycloalkylketone group, C1-4 alkyl carbonyl, sulfonamido, sulfonyloxy, amino sulfonyl, amino sulfonyloxy, C1-4 alkyl sulfonamido, C1-4 alkyl amino sulfonyl, C1-4 alkyl amino sulfonamido, C1-4 alkyl sulfonyloxy, C1-4 alkyl amino sulfonyloxy, C1-4 alkyl amino carbonyloxy, heterocyclic, C1-4 alkyl amino, C3-6 cycloalkyl amino, tetrahydrofuranyloxy, tetrahydrofuranyl amino, C1-4 alkyl carbonyl amino, C1-4 alkoxy, C1-4 alkylthio, C3-6 cycloalkoxy, C3-6 heterocycloalkyl or C1-4 alkyl, wherein the substituent is one or more selected from the group consisting of deuterium, halogen, cyano, hydroxyl, phenyl, C1-3 alkyl, C1-3 deuteroalkyl or C1-3 haloalkyl;
R14 is a cyano, carboxyl, or substituted or non-substituted group of C1-4 alkoxy carbonyl, aminocarbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, N-pyrrolidinyl carbonyl, amino sulfonyl, C1-4 alkyl amino sulfonyl, heterocyclic group, tetrahydrofuranyloxy, C1-4 alkoxy, C3-6 cycloalkyloxy, or C1-4 alkyl, wherein the substituent is one or more selected from the group consisting of deuterium, halogen, cyano, hydroxyl, C1-3 alkyl or C1-3 haloalkyl;
R15 is hydrogen, deuterium, halogen, cyano, C1-2 alkyl, C1-2 alkoxy, carboxyl, or C1-3 alkyl substituted amide.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein the compound has the structure shown in formula (V) or formula (VI),
R1, R2 or R3 is independently C1-3 alkoxy respectively; or, R1 and R2 or R2 and R3 are joined together to form —O—R17—O— group, wherein R17 is C1-2 alkyl;
R4 is hydrogen, deuterium, halogen, or cyano;
R9 is hydrogen or C1-3 alkyl;
X is —C(═O)— or —S(═O)2— group;
R10 is C1-3 alkyl, substituted C1-3 alkyl, C3-6 cycloalkyl, amino, C1-4 alkyl amino, C1-3 alkoxy or vinyl, or R9 forms
group with N—X—R10; wherein the substituent is selected from one or more of deuterium and cyano;
R11 is hydrogen, deuterium or halogen;
R12 is hydrogen, deuterium, halogen, cyano, or substituted or non-substituted group of the following: C1-3 alkyl, C3-5 cycloalkyl, C1-3 alkoxy, morpholinyl, C1-4 alkylamino carbonyl or C1-4-alkoxy carbonyl; wherein the substituent is selected from one or more of deuterium and halogen; and
(a) when R12 is hydrogen, R13 is a cyano, aldehyde group, carboxyl, borono, substituted C1-4 alkoxy, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, phenyl amino carbonyl, pyridinyl amino carbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, N-pyrrolidyl carbonyl, piperazinyl carbonyl, morpholinyl carbonyl, pyrrolidonyl, oxazolidinonyl, 3-morpholinonyl, C1-2 alkyl carbonyl, sulfonamido, sulfonyloxy, amino sulfonyl, amino sulfonyloxy, C1-4 alkyl sulfonamido, C1-4 alkyl amino sulfonyl, C1-4 alkyl amino sulfonamido, C1-4 alkyl amino sulfonyloxy, C1-4 alkyl amino carbonyloxy, tetrazolyl, triazolyl, imidazolyl, pyrazolyl, morpholinyl, C1-4 alkyl thio, C3-6 cycloalkyloxy or tetrahydrofuranyloxy, the substituent is one or more selected from the group consisting of deuterium, halogen, cyano, hydroxyl, phenyl, pyridyl, C1-3 alkyl, C1-3 deuteroalkyl or C1-3 haloalkyl;
(b) when R12 is not hydrogen, R13 is cyano, aldehyde group, carboxyl, borono, or substituted or non-substituted group of C1-4 alkoxy carbonyl, amino carbonyl, phenyl amino carbonyl, pyridinyl amino carbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, pyrrolidonyl, 2-oxazolidinonyl, 3-morpholinonyl, pyrrolidinyl carbonyl, methylpiperazinyl carbonyl, morpholinyl carbonyl, C1-4 alkyl carbonyl, sulfonamido, sulfonyloxy, amino sulfonyl, amino sulfonyloxy, C1-4 alkyl sulfonamido, C1-4 alkyl amino sulfonyl, C1-4 alkyl amino sulfonamido, C1-4 alkyl sulfonyloxy, C1-4 alkyl amino sulfonyloxy, C1-4 alkyl amino carbonyloxy, heterocyclic, C1-4 alkyl amino, C3-6 cycloalkyl amino, tetrahydrofuranyloxy, tetrahydrofuranyl amino, C1-4 alkyl carbonyl amino, C1-4 alkoxy, C1-4 alkylthio, C3-6 cycloalkoxy, C3-6 heterocycloalkyl or C1-4 alkyl, wherein the substituent is one or more selected from the group consisting of deuterium, halogen, cyano, hydroxyl, phenyl, pyridyl, C1-3 alkyl, C1-3 deuteroalkyl or C1-3 haloalkyl;
R14 is a cyano, carboxyl, or substituted or non-substituted group of C1-4 alkoxy carbonyl, aminocarbonyl, C1-4 alkyl amino carbonyl, C1-4 alkoxy carbonyl amino, C1-4 alkyl amino carbonyl amino, N-pyrrolidinyl carbonyl, amino sulfonyl, C1-4 alkyl amino sulfonyl, pyrrolidyl, oxazolidyl, isooxazolidyl, piperazinyl, morpholinyl, piperidyl, tetrahydrofuranyl, tetrahydrothiophenyl, hexahydropyrimidyl, tetraazolidyl, triazolidyl, tetrahydrofuranyloxy, C1-4 alkoxy, C3-6 cycloalkyloxy, or C1-4 alkyl, wherein the substituent is one or more selected from the group consisting of deuterium, halogen, cyano, hydroxyl, C1-3 alkyl or C1-3 haloalkyl;
R15 is hydrogen, deuterium, halogen, methyl, ethyl, halomethyl or haloethyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein, R9 is hydrogen, methyl or ethyl;
X is —C(═O)— or —S(═O)2— group;
R10 is methyl, ethyl, cyclopropyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, methoxy, ethoxy, cyanomethyl, or cyanoethyl, or R9 is joined together with N—X—R10 to form

### Claim 5 (depends on 1)

The compound claim 1, wherein, R12 is hydrogen, deuterium, methyl, ethyl, halogen, cyano, methoxy, ethoxy, morpholinyl, aminocarbonyl, phenyl aminocarbonyl, methyl aminocarbonyl, methyl formate or ethyl formate; and
(a) when R12 is hydrogen, R13 is cyano, aldehyde group, carboxyl, borono, halomethoxyl, haloethoxyl, deutero methoxyl, deuteroethoxyl, methoxy carbonyl, ethoxy carbonyl, aminocarbonyl, phenyl aminocarbonyl, pyridinyl aminocarbonyl, methyl aminocarbonyl, deuteromethylaminocarbonyl, halomethyl aminocarbonyl, ethyl aminocarbonyl, dimethylaminocarbonyl, methoxy carbonyl amino, ethoxy carbonyl amino, (methoxy carbonyl)(methyl) amino, methyl amino carbonyl amino, ethyl amino carbonyl amino, dimethyl amino carbonyl, pyrrolidyl carbonyl, cyanopyrrolidyl carbonyl, piperazinyl carbonyl, methyl piperazinyl carbonyl, morpholinyl carbonyl, pyrrolidonyl, 2-oxazolidonyl, 3-morpholinonyl, methyl carbonyl, ethyl carbonyl, sulfonyl amino, sulfonyloxy, methyl sulfonyloxy, ethyl sulfonyloxy, hydroxyl sulfonyloxy, amino sulfonyl, amino sulfonyloxy, methyl sulfonyl amino, ethyl sulfonyl amino, methyl amino sulfonyl, methyl amino sulfonyl amino, methyl amino sulfonyloxy, N-ethyl methyl amino carbonyloxy, tetrazolyl, triazolyl, imidazolyl, pyrazolyl, morpholinyl, methylthio, ethylthio, halomethylthio, haloethylthio, deuteromethylthio, deuteroethylthio or tetrahydrofuranyloxy;
(b) when R12 is not hydrogen, R13 is cyano, aldehyde group, carboxyl, borono, methoxy carbonyl, ethoxy carbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminocarbonyl, phenylamino carbonyl, pyridyl amino carbonyl, ethyl aminocarbonyl, halomethyl aminocarbonyl, deuteromethyl aminocarbonyl, (methoxycarbonyl)(methyl) amino, methyl aminocarbonyl amino, ethyl aminocarbonyl amino, dimethyl amino carbonyl amino, pyrrolidyl carbonyl, cyanopyrrolidyl carbonyl, piperazinyl carbonyl, methyl piperazinyl carbonyl, morpholinyl carbonyl, pyrrolidonyl, 2-oxazolidinonyl, 3-morpholinonyl, methyl carbonyl, ethyl carbonyl, sulfonyl amino, sulfonyloxy, hydroxyl sulfonyloxy, amino sulfonyl, amino sulfonyloxy, methyl sulfonyl amino, ethyl sulfonyl amino, methyl amino sulfonyl, ethyl amino sulfonyl, methyl amino sulfonyl amino, methyl amino sulfonyloxy, N-ethyl methyl amino carboxyloxy, tetrazolyl, triazolyl, methyl amino, ethyl amino, tetrahydrofuranyloxy, tetrahydrofuranyl amino, methyl carbonyl amino, methoxy, halomethoxy, deuteromethoxy, ethoxy, haloethoxy, deuteroethoxy, methylthio, halomethylthio, deuteromethylthio, ethylthio, haloethylthio, deuteroethylthio, tetrahydrofuranyl, piperazinyl, piperidyl, methylpiperidyl, imidazolyl, pyrazolyl, morpholinyl, pyrrolidinyl, tetrahydrocarbazolyl, morpholinyl, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, halomethyl or haloethyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein,
R11 is hydrogen or deuterium;
R14 is methylaminocarbonyl, dimethylaminocarbonyl, cyano, methoxy carbonyl, ethoxy carbonyl, carboxyl, N-pyrrolidyl carbonyl, tetrahydrofuranyloxy, methoxy, ethoxy, cyclopropoxy, halomethoxy, haloethoxy, deuteromethoxy, deuteroethoxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, tetraazolyl, triazolyl, morpholinyl, halomethyl or haloethyl;
R15 is hydrogen, deuterium, methyl, ethyl, halomethyl, or haloethyl.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the compounds are selected from the group consisting of:

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the compounds claim 1 as active ingredient, supplemented by pharmaceutically acceptable excipients.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is used as anti-inflammatory or analgesic drugs.

### Claim 10 (depends on 1)

A method for treating a disease comprising a step of administering the compound of claim 1 to a subject in need, wherein the disease is selected from the group consisting of arthritis, acute gouty arthritis, rheumatoid arthritis, inflammatory storms and coronavirus pneumonia.
